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August 2019 TKI in NSCLC and Refractory Leptomeningeal Disease 1401failure was defined as diagnosis of LM on TKI, or progres-
sion of known LM on TKI.
Results: Ninety-two patients were included, median age of
60 years, predominantly female (68%), never-smokers
(74%). EGFR mutations included L858R (45%), exon 19
deletions (28%), or other mutations (14%). Median time to
LM diagnosis was 18.5 months after initial diagnosis of
advanced NSCLC. LM was diagnosed after a median of 2
(range: 0–9) systemic therapies. Median overall survival
from LM diagnosis was 6.1 months (95% confidence in-
terval [CI]: 4.2–7.6 months). Among 87 patients with TKI
failure, patients rechallenged with TKI (n ¼ 50) had a me-
dian LM overall survival of 7.6 months (95% CI: 5.7–10.9)
compared to 4.2 months (95% CI: 1.6–6.7) in patients
without further therapy. Overall, 60% of patients rechal-
lenged with TKI experienced clinical benefit (clinical
response or stable disease >2 months), and 23% were
treatment failure-free at 6 months. Clinical benefit was re-
ported in 11 of 20 (55%) patients treated with erlotinib
after afatinib or gefitinib. Strategies based on increasing
dose intensity (n ¼ 17) yielded clinical benefit in 59% of
patients. All four patients who received osimertinib after
first- and second-generation TKI experienced clinical
benefit.
Conclusions: TKI rechallenge strategies, including dosing
intensification, may improve clinical outcomes of patients
with LM from EGFR-mutated NSCLC after initial TKI failure.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: NSCLC; EGFR; Tyrosine kinase inhibitor; Lep-
tomeningeal metastasesIntroduction
Lung cancer is the leading cause of death from cancer
worldwide.1 Targeted molecular therapies provided
significant improvements in outcomes of patients pre-
senting with somatic EGFR mutations, found in up to
15% of NSCLC cases in the western world.2 Although
underdiagnosed, leptomeningeal metastases (LM) will
arise in w10% of patients with EGFR-mutated NSCLC,
leading to dismal outcomes: survival in this population
does not exceed 1 year in the era of EGFR-directed
tyrosine kinase inhibitors (TKIs).3,4
Activity of TKIs in EGFR-mutated patients with LM has
been only described in relatively small retrospective
studies and phase I trials. In addition, cerebrospinal fluid
(CSF) penetration may vary for each drug type and
dosing.5,6 In a retrospective study of 21 patients, 48% had
cytologic responses to standard dose erlotinib, whereas
higher-dose regimens have shown potential to rescue
subsets of patients refractory to standard dose therapy.7-9High-dose osimertinib (160 mg) has been studied in a
phase I study and provided clinical stability or improve-
ment at 12 weeks in 23 of 32 (72%) patients.10 Likewise,
novel EGFR TKIs with high capability to penetrate the
blood brain barrier, such as AZD3759, have reported
clinical activity in EGFR-mutant patients with LM.11
Nowadays, several EGFR-TKIs are available in EGFR-
mutant NSCLC, and optimal therapeutic sequence in this
population remains unknown. As LMs often develop dur-
ing systemic TKI therapy, exploring the activity of subse-
quent TKI therapy after initial TKI failure is essential.
Herein, we report a joint international effort to
evaluate the activity of EGFR-directed TKIs in a large
cohort of EGFR-mutated NSCLC patients with LM after
first TKI failure.
Material and Methods
Patients
We included consecutive patients with EGFR-
mutated NSCLC and LM across five European in-
stitutions: Gustave Roussy, Villejuif, France; Centre
Francois Baclesse, Caen, France; Lille University Hos-
pital, Lille, France; Strasbourg University Hospital,
Strasbourg, France; and Maastricht UMCþ, Maastricht,
Netherlands. We collected clinical characteristics of
patients as well as disease-related features including
imaging, histology, and molecular profiling. Diagnosis of
LM was assessed either by cytology of the CSF (Euro-
pean Association of Neuro-Oncology [EANO]-European
Society for Medical Oncology [ESMO]–confirmed LM),
or by concordant clinical and radiologic assessments
including at least brain magnetic resonance imaging
(MRI) (EANO-ESMO–probable LM).12 In case of EANO-
ESMO–probable LM, MRI was to be performed before
any lumbar puncture to avoid nonspecific lep-
tomeningeal enhancement. TKI failure was defined as:
(1) diagnosis of LM during systemic therapy with TKI
or (2) progression of known LM on treatment with TKI.
TKI rechallenge was defined as a new line of TKI after
TKI failure, including administration of other TKI, or
regimen adaptations such as dosing modifications of
combination therapies. We analyzed outcomes accord-
ing to systemic and central nervous system (CNS)–
directed treatments.
Statistical Analysis
We defined LM overall survival (OS) as time from LM
diagnosis to death or last follow-up, and TKI OS from
TKI rechallenge to death or last follow-up. Time-to-
treatment failure (TTF) was defined as time from TKI
rechallenge to treatment discontinuation or death.
Patients surviving without treatment failure event were
censored at date of last visit. Clinical response was
Table 1. Baseline Characteristics of the Study Population
Baseline Characteristics N ¼ 92
Median age, (range) y 60 (26–79)
Sex
Male 29 (32)
Female 63 (68)
Smoking
Smoker 22 (24)
Nonsmoker 68 (74)
Unknown 2 (2)
Stage at diagnosis
I 3 (3)
II 1 (1)
III 6 (7)
IV 78 (85)
Unknown 4 (4)
Median number of metastatic sites at
diagnosis, (range)
1 (0–5)
1402 Flippot et al Journal of Thoracic Oncology Vol. 14 No. 8assessed using physician-reported neurologic outcomes.
Clinical benefit was defined as clinical response or stable
disease confirmed at least 2 months after treatment
initiation. Survival analyses were performed using
Kaplan-Meier estimates, and reported along with their
95% confidence intervals (95% CIs). A Cox proportional
hazards regression model was used to evaluate the as-
sociation between TKI rechallenge and OS, providing
hazard ratio (HR) and 95% CI adjusted for the following
characteristics: age; Eastern Cooperative Oncology
Group performance status classification at the time of
TKI failure; number of lines of therapy before TKI fail-
ure; context of TKI failure (diagnosis of LM on TKI, or
progression of known LM on TKI). Median follow-up
was calculated using the reverse Kaplan Meier method.
Statistical analyses have been performed using NCSS 12
(NCSS, LLC) and R Studio.EGFR mutation
Exon 21 L858R 41 (45)
Exon 19 del 26 (28)
Other 13 (14)
Unknown 12 (13)
Median time to LM onset, (range), mo 18.5 (0–106)
LM diagnosis
Cytology confirmed 58 (63)
Imaging and symptoms 34 (37)
Symptoms related to LM 85 (92)
Concurrent brain metastases 61 (66)
Radiation therapy for brain metastases
Radiation therapy 29 (32)
Including: WBRT 18 (20)
SRS 8 (9)
WBRT þ SRS 3 (3)
No. of systemic treatments before LM
diagnosis, median (range)
2 (0–9)
Values are shown as n (%) or median (range).
LM, leptomeningeal metastases.Results
Patients
Ninety-two patients with EGFR-mutated NSCLC and
leptomeningeal dissemination were included, diagnosed
with LM between August 2003 and October 2018. Me-
dian follow-up was 5.6 months (range: 0.1 to 38.6
months). Most patients were female (68%), never-
smokers (74%), and had stage IV disease at diagnosis
(85%). EGFR mutations were determined by gene panel
sequencing or polymerase chain reaction–based assays
and were predominantly L858R substitutions (45%) or
exon 19 deletions (28%). Rare activating EGFR muta-
tions were found in 14% of patients, whereas 13%
had activating EGFR mutations of unspecified subtype.
Acquired T790M mutations were reported in 15 patients
before LM diagnosis.
Median time from initial cancer diagnosis to LM
diagnosis was 18.5 months (range 0–106 months). LM
was diagnosed after systemic therapy consisting in TKI
in 52 of 92 (56%) patients, chemotherapy in 32 of 92
(35%), or before any systemic therapy for stage IV dis-
ease in 8 of 92 (9%) patients. Overall, patients received a
median number of two systemic therapies (range: 0–9)
before diagnosis of LM. Concurrent brain metastases
were reported in 61 of 92 (66%) of patients at LM
diagnosis, among whom 29 were treated with radiation
therapy (Table 1). LM was confirmed by cytology in 63%
of patients (EANO-ESMO–confirmed LM), whereas the
remaining 37% had typical symptoms and imaging
(EANO-ESMO–probable LM). At LM onset, 85 of 92
(92%) patients experienced one or more symptoms
related to LM. Most frequent symptoms included head-
ache (26%), cerebellar syndrome (17%), cognitive dis-
orders (21%), and seizures (10%) (Supplementary
Table 1).Overall Survival From LM Diagnosis
Among the entire study population, LM OS was 6.1
months (95% CI: 4.2–7.6), and the 12-month LM OS rate
was 27% (95% CI: 18%– 37%) (Fig. 1A).
TKI failure occurred in 87 patients: 52 who had LM
diagnosis during TKI, and 35 who had progression of
known LM after TKI. Five additional patients were not
treated with TKI at LM onset and did not receive any
further treatment. Overall, 50 of 87 (57%) patients were
rechallenged with TKI after TKI failure. Among them, 37
were rechallenged after a diagnosis of LM on TKI, and 13
had known LM that progressed on previous TKI.
LM OS in patients rechallenged with TKI was 7.6
months (95% CI: 5.7–10.9) compared to 4.2 months
(95% CI: 1.6–6.7) in patients without any further ther-
apy at TKI failure. The survival benefit was independent
from age, Eastern Cooperative Oncology Group perfor-
mance status, previous lines of therapy, and context of
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Figure 1. Overall survival in the study population. (A) Overall survival from leptomeningeal metastases diagnosis. (B) Overall
survival according to systemic therapy for refractory leptomeningeal metastases.
August 2019 TKI in NSCLC and Refractory Leptomeningeal Disease 1403TKI failure, with an adjusted HR for death of 0.42 (95%
CI: 0.24–0.75) (Supplementary Table 2). Respective 12-
month OS rates in both groups were 32% (95% CI:
18%–46%) and 24% (95% CI: 10%–39%) (Fig. 1B).Therapeutic Strategies and Outcomes From TKI
Rechallenge
Among 50 patients rechallenged with TKI, 44 (88%)
were refractory to first- or second-generation TKI,
including erlotinib (19), afatinib (5), or gefitinib (20). Six
patients (12%) were refractory to third-generation TKI,
including osimertinib (5) and rociletinib (1). Therapeuticsequences after initial TKI failure are detailed in Table 2.
Most patients (60%) had TKI switch, whereas 40% were
treated with the same TKI but with more intensive
regimens, including either dose intensification aiming at
increasing CNS diffusion (34%) or combination thera-
pies (6%) (Supplementary Table 3). Patients were
treated with a median number of two systemic therapies
after initial TKI failure (range: 1–5). Eight patients
(16%) received additional intrathecal therapy.
Median TKI OS was 6.8 months (95% CI: 3.7–8.0)
across all 50 rechallenged patients. Patients who were
rechallenged following LM diagnosis on TKI had longer
TKI OS compared to patients rechallenged after
Table 2. Therapeutic Sequence in Patients With TKI
Rechallenge at Initial TKI Failure (n ¼ 50)
Treatment n (%)
Regimen switch
Erlotinib 22 (44)
From first- / second-generation TKI 20 (40)
From third-generation TKI 2 (4)
Afatinib/gefitinib 4 (8)
From first- / second-generation TKI 4 (8)
Osimertinib 4 (8)
From first-/second-generation TKI 4 (8)
Regimen adaptation
Increased dose intensity 17 (34)
From first-/second-generation TKI 13 (26)
From third-generation TKI 4 (8)
Combinations 3 (6)
From first-/second-generation TKI 3 (6)
Median no. of systemic therapies after
TKI failure (range)
2 (1-5)
Intrathecal therapy for refractory LM 8 (16)
Values are n (%) unless otherwise stated.
TKI, tyrosine kinase inhibitor; LM, leptomeningeal metastases.
1404 Flippot et al Journal of Thoracic Oncology Vol. 14 No. 8progression of known LM on TKI, with respective me-
dian TKI OS of 7.8 months (95% CI: 5.7–10.6) and 3.2
months (95% CI: 1.8–4.0), adjusted HR for death 0.42
(95% CI: 0.19–0.92) (Supplementary Table 4).
Median TTF from TKI rechallenge was 2.9 months
(95% CI: 2.1–3.7), and 6-month treatment failure–free
rate was 23% (95% CI: 11%–35%) (Fig. 2 and
Supplementary Fig. 1). No significant difference in me-
dian TTF was observed between patients rechallenged50%
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23%
Months f
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Figure 2. Time-to-treatment failure of patients treafter LM diagnosis on TKI and patients rechallenged af-
ter progression of known LM on TKI, with respective
TTF of 3.3 months (95% CI: 2.1–3.9) and 2.3 months
(95% CI: 1.4–3.1).
Forty-nine patients could be evaluated for response
to TKI rechallenge. One patient was lost to follow-up
immediately after subsequent TKI initiation and there-
fore not evaluable for response. Clinical response and
clinical benefit occurred in 28% and 60% of patients,
respectively. Outcomes of patients by treatment sub-
groups are detailed in Table 3.
Erlotinib was the most frequent TKI used for TKI
rechallenge, in 22 of 50 (44%) patients, including 20
patients who had received prior afatinib or gefitinib, and
two who had received prior third-generation TKI. Clin-
ical response was observed in 6 of 22 (27%) and clinical
benefit in 12 of 22 (54%) patients (Table 3). Median TTF
was 2.7 months (95% CI: 1.3–3.7), and 24% of patients
were treatment failure–free at 6 months (95% CI: 6%–
42%). Of 20 patients who received erlotinib after afati-
nib or gefitinib failure, 5 (25%) experienced clinical
response and 11 (55%) clinical benefit. One clinical
response was observed in a patient treated with erloti-
nib following osimertinib, in a disease without docu-
mented T790M mutation.
Seventeen (34%) patients received dose-intensified
regimens at TKI rechallenge (Supplementary Table 3).
Among those, 6 of 17 (35%) had clinical response and 10
of 17 (59%) clinical benefit. At 6 months, 24% were
treatment failure–free (95% CI: 3%–44%). Four patientsrom treatment start
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August 2019 TKI in NSCLC and Refractory Leptomeningeal Disease 1405with known T790M mutations had increased dose in-
tensity from osimertinib-based regimen, leading to clin-
ical benefit for all of them, including three partial
responses and one stable disease. Dose modifications
were well tolerated. No grade 3/4 toxicities were re-
ported with patients receiving increased dose of first- or
second-generation TKIs. Only two patients discontinued
osimertinib 160 mg due to grade 3 adverse events
including rash and diarrhea.
Four patients switched to osimertinib after first- or
second-generation TKI, among whom three had evidence
of T790M mutation at initial TKI failure. All derived
clinical benefit with three having stable diseases and one
having clinical response, with prolonged median TTF of
10.1 months. All but one of four patients was alive at the
time of the analysis with a median follow-up of 12.6
months after TKI rechallenge.
Patients treated with afatinib or gefitinib after other
first- or second-generation TKI had clinical responses in
25% and clinical benefit in 50%, but a short median TTF at
1.1 months (95% CI: 0.1–3.5). No clinical responses were
reported in patients treated with combination therapies
using the same TKI (n ¼ 3).
Seventeen patients received brain radiation therapy
for brain metastases and/or LM before TKI rechallenge,
including 13 treated by whole brain radiation therapy.
No significant difference in disease control or TTF was
observed in this subgroup compared to patients who did
not receive radiation therapy, regardless of radiation
therapy modality. Additional intrathecal therapy (n ¼ 8)
was not associated with improved clinical benefit nor
TTF (Supplementary Table 5).
Discussion
This large-scale retrospective study shows that TKI
rechallenge provides substantial activity after TKI fail-
ure. We observed prolonged LM OS (7.6 versus 4.2
months) in patients who were rechallenged with a TKI,
compared to those who were not.
High response rates and prolonged TTF were
observed in patients who received erlotinib after first- or
second-generation TKI, or who received high-dose erlo-
tinib. These data support the hypothesis that therapeutic
resistance in the context of LMs may be related to
limited CNS diffusion.13,14 Erlotinib has better brain-
blood-barrier penetration than afatinib or gefitinib, and
dose-intensification strategies have been proven to
improve CNS diffusion of TKIs.5,13,15 Prospective studies
have confirmed the feasibility of TKI dose increase in
clinical practice, notably for erlotinib and osimerti-
nib.10,16 Thus, current data support the use of rescue
high-dose TKI at the time of standard-dose TKI failure in
EGFR-mutant patients with LM. However, this strategy
should be considered only in patients with predominant
1406 Flippot et al Journal of Thoracic Oncology Vol. 14 No. 8CNS disease, as higher-dose therapies may not rescue
extracranial resistance after TKI failure.17
Although few patients have been treated with third-
generation TKI in our cohort, long-term survival has
been reported in patients receiving osimertinib including
responses that lasted more than 1 year after TKI
rechallenge. This is in line with recent reports on intra-
cranial activity of osimertinib for both brain and
LMs.6,10,18,19 Osimertinib may be highly active by tar-
geting diseases which acquire T790M mutations, as well
as through high CNS concentrations in all-comers. In our
study, all patients but one who had TKI rechallenge with
osimertinib had a documented T790M mutation. As a
consequence, we cannot generate data on the LM control
by osimertinib used upfront in patients who are T790M-
negative compared to a sequential strategy. Dedicated
studies will be essential to assess the activity of osi-
mertinib in this population as this compound may
significantly improve outcomes in this population.
Recent insights into LM biology might help elaborate
better therapeutic strategies for these patients. LMs
might have different molecular alterations compared to
solid brain metastases. In particular, LMs have been
found to be enriched in EGFR, MET proto-oncogene, re-
ceptor tyrosine kinase (MET), and tumor protein p53
(TP53) mutations, whereas they rarely harbor KRAS al-
terations compared to other solid metastases from
NSCLC.20-22 Tailoring therapy to molecular alterations
found in the CSF has been reported to be feasible while
providing clinical benefit in subsets of patients.22 In this
context, the use of CSF as liquid biopsy specimens may
facilitate translational research programs and help to
personalize subsequent treatment.21
The choice of clinical endpoints in our study shows
the difficulties encountered when assessing response
of LMs. MRI evaluation leads to false-negative assess-
ments in up to 30% of patients at diagnosis, whereas
sensitivity of cytology can be as low as 50%.23 Follow-
up is equally difficult with the lack of specific evalua-
tion criteria and high variability. At present, clinical
outcomes remain a key variable for the evaluation of
LMs, considering the high proportion of patients who
experience neurologic symptoms and the fact that
therapeutic decisions were guided by clinical outcomes
in our cohort. The Response Assessment in Neuro-
Oncology and EANO-ESMO working groups estab-
lished frameworks relying on neurologic evaluation,
MRI of the CNS, and cytology of the CSF to assess LM
diagnosis and follow-up, which may help improve
clinical management and drug development in this
particular population.12,24
In conclusion, our study shows that a strategy using
various lines of EGFR TKIs leads to a significant
OS benefit in patients with LMs. Regimen switch orstrategies using higher dosing may help overcome
resistance to TKI in a context of CNS dissemination and
improve outcomes. Evaluation of osimertinib in patients
with EGFR-mutated LMs regardless of T790M status is
warranted and could challenge standard of care in this
population. Standardized leptomeningeal assessments
and translational research programs are needed to bet-
ter understand resistance mechanisms and improve
current therapeutic strategies.
Supplementary Data
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